Mark Nelson is a Neurology physician. ClinicalTrials.gov lists 13 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
360 Merrick Rd Fl 1
Lynbrook, NY 115632526
Telephone
516-887-3516Provider last certified this registry record 24 Sept 2024.
Clinical trials
- Non-Responsive Diabetic Macular Edema and Spironolactone
Sponsor: Wake Forest University Health Sciences
- Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment
Sponsor: Wake Forest University Health Sciences
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
64 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202531 payments
- Neurocrine BioSciences, Inc.Program year20257 payments
- UCB, Inc.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
92.9%Cholinesterase Inhibitor14%Donepezil Hcl87%Rivastigmine9%Pyridostigmine Bromide3%Pyridostigmine Bromide Er1%Part D<11 patientsSSRI13.2%Sertraline Hcl44%Escitalopram Oxalate39%Trazodone Hcl8%Fluoxetine Hcl5%Citalopram Hbr2%Paroxetine Hcl2%Part D<11 patients+ 30 more classes in this area
Musculoskeletal
2%Central alpha-2 Adrenergic Agonist0.6%Tizanidine Hcl100%Part D≥16 patientsgamma-Aminobutyric Acid-ergic Agonist0.6%Baclofen100%Part D≥15 patients+ 3 more classes in this area
Blood & clotting
1.6%P2Y12 inhibitor1.6%Clopidogrel100%Part D≥40 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”